Role of left atrial appendage occlusion in patients with HeartMate 3. (18th October 2021)

• Record Type: Journal Article
• Authors: Melehy, Andrew; O'Connell, Gillian; Ning, Yuming; Kurlansky, Paul; Kaku, Yuji; Topkara, Veli; Yuzefpolskaya, Melana; Colombo, Paolo C; Sayer, Gabriel; Uriel, Nir; Naka, Yoshifumi; Takeda, Koji
• Is Part Of: Interactive cardiovascular and thoracic surgery. Volume 34:Number 4(2022)
• Page Start: 668
• Page End: 675
• Publication Date: 2021-10-18
• Subjects: Left atrial appendage occlusion -- HeartMate 3 -- Mechanical circulatory support -- Thromboembolism; Chest -- Surgery -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; 616.1
• DOI: 10.1093/icvts/ivab285
• Languages: English
• ISSNs: 1569-9293

Abstract

Abstract: OBJECTIVES: Left atrial appendage occlusion (LAAO) at the time of implantation may reduce thromboembolic events (TEs) during continuous-flow left ventricular assist device support. The HeartMate 3 (HM3) reduces TEs overall, but the efficacy of LAAO in HM3 is unknown. METHODS: Adults receiving first HM3 implantation from November 2014 through December 2019 at a single, large medical centre were retrospectively reviewed. TEs included device thrombosis and ischaemic stroke. Patients were classified by whether they received LAAO or not. Incidence of TEs was compared between groups using cumulative incidence curves with competing risks (death and heart transplant) and risk factors for TEs were assessed with Fine and Gray competing risk regression. RESULTS: A total of 182 patients received HM3, of whom 99 (54%) received LAAO versus 83 (46%) who did not. There were 14 TEs, including 13 strokes (7%) and 1 pump thrombosis (0.5%). No significant difference in the incidence of TEs in each group was found (Gray's test: P = 0.35). LAAO was not associated with TEs in multivariable Fine–Gray analysis ( P = 0.10) and no significant risk factors for TEs were found. There were zero disabling strokes in those who received LAAO compared to 6 (7%) in those who did not receive LAAO ( P = 0.008). CONCLUSIONS: A low number of TEs was observed in HM3 recipients. LAAO did not further reduce the overall rate of TEs in this patient population, though its use may be beneficial in preventing disabling ischaemic strokes after HM3 implantation. Abstract : Thromboembolic events (TEs) such as ischaemic stroke and device thrombosis have historically been significant complications associated with non-HeartMate 3 (HM3) continuous-flow left ventricular assist devices (LVADs) [1–4].